Twenty Years Later: A Grim Anniversary as Mount Sinai Remains a Lifeline for 9/11 Responders

On the evening of Tuesday, September 11, 2001—with fires burning at the site of where the twin towers had stood that morning and several thousand people still unaccounted for—a group of physicians from the Mount Sinai Selikoff Centers for Occupational Health met to discuss a plan of action for treating survivors and first responders who had rushed in to help.

Protégés of the late Irving Selikoff, MD—a pioneering researcher who was the first to definitively link asbestos exposure to lung cancer—these physicians knew how dangerous the air was at the site of the attack, which had been reduced to 1.8 million tons of burning rubble. The toxic stew of chemicals would later be found to include major hazards to human health, such as lead and other heavy metals, benzene, dioxin, and asbestos. The physicians also knew that serious illnesses could develop decades after an individual’s initial exposure, lessons they had learned from Dr. Selikoff and his groundbreaking research in the 1960s.

Over the course of their first meeting and several subsequent ones that included colleagues such as David Prezant, MD, Chief Medical Officer of the Fire Department of the City of New York (FDNY), the Mount Sinai physicians established a blueprint for what is now the World Trade Center (WTC) Health Program.

Today, 20 years later, the WTC program continues to receive new patients. It consists of six New York City-area medical centers, including Mount Sinai, and a separate treatment center exclusively for FDNY members. Together, the centers treat more than 80,000 emergency responders—firefighters, police, recovery and cleanup workers—as well as 30,000 people who worked, lived, or went to school near the disaster zone in lower Manhattan. Their medical care will be funded through 2090, under the federal James Zadrogra 9/11 Health and Compensation Act, which was signed into law in 2011.

“The Selikoff Centers had exceptional doctors and they worked their fingers to the bone getting this program off the ground,” says Michael Crane, MD, MPH, who joined Mount Sinai in 2006 as Director of the World Trade Center Health Program Clinical Center at Mount Sinai. “Their incredible dedication got this going. It was hardscrabble, making phone calls and asking people to speak out about the program. They were helped by community and civic leaders and members of Congress who got behind this. Their story is really an inspiration.”

Dr. Crane, whose program at Mount Sinai cares for roughly 23,000 responders, was medical director of Con Edison’s health program on 9/11. Immediately following the attacks, he was down at the site making sure Con Edison’s recovery workers had proper masks and breathing protection. But that was not the case for many other responders. The filters on their masks clogged up after an hour and workers were either too busy to replace them or could not find extra masks.

Sandra Lowe, MD, talks about what we’ve learned about trauma and resilience from treating responders. Her answers have implications for COVID-19 and beyond. Dr. Lowe is Medical Director at the World Trade Center Mental Health Program Clinical Center of Excellence at Mount Sinai.

 

“You’d see the masks hanging off their faces,” says Dr. Crane. “They were running in to save people’s lives. They ran in without appropriate equipment and suffered the consequences.”

The dedication of the recovery workers was inspiring, says Dr. Crane. “So many of them had friends or relatives or people they knew or had trained with down there. Guys who ran down there had built the towers. So it was a tremendous emotional shock. They were energized by this passion to do something about it. So many of them said the same thing: ‘It’s family. I want to find them.’ It was deep and personal and real.”

Michael Crane, MD, MPH, left, and Julia Nicolaou Burns, Administrative Director, Selikoff Centers for Occupational Health

On 9/11, Craig L. Katz, MD, was the newly appointed Director of The Mount Sinai Hospital’s Psychiatry Emergency Room. But it was his leadership of the nonprofit organization, Disaster Psychiatry Outreach, which he had founded during his medical residency, which led to his direct involvement with the families of the victims, survivors, and responders. Almost immediately, Dr. Katz helped organize volunteer psychiatrists who met informally with these groups down at Ground Zero or at the Family Assistance Center that New York City had established downtown.

At the time, lung screenings for responders were being funded by the National Institute for Occupational Safety and Health (NIOSH), but no federal funding had been allocated for mental health. Yet the psychological effects of the troubling rescue and recovery mission were beginning to show.

A few months after the attacks, Dr. Katz says Mount Sinai’s Psychiatry Department received a phone call from the late Stephen Levin, MD, then Medical Director of the Mount Sinai Selikoff Centers for Occupational Health, who said, “ ‘I have all these rescue and recovery workers coming into my office and they’re crying. I don’t know what to do with them. I’m looking at lung exposures and they’re crying.’”

Craig L. Katz, MD

Looking to assist the workers, Dr. Katz, currently a Clinical Professor in the departments of Psychiatry, Medical Education, and System Design and Global Health, at the Icahn School of Medicine at Mount Sinai, wrote a three-page grant proposal to the private Robin Hood Foundation requesting funding for mental health. “That was the birth of the mental health program for recovery workers,” he says.

The Robin Hood Foundation would go on to provide the program with more than $6 million until 2011, when the Zadroga Bill was enacted, according to Dr. Katz. “Robin Hood typically funds underserved populations,” he says. “They agreed the rescue and recovery workers were an underserved population. They were largely men who don’t readily seek help for mental health issues. These blue collar guys were not our usual customers.”

Today, Mount Sinai’s World Trade Center (WTC) Mental Health Program actively treats close to 700 individuals under the leadership of Sandra M. Lowe, MD, Medical Director. “The people involved in the recovery and restoration operations were exposed to so much trauma,” says Dr. Lowe. “Some individuals developed post-traumatic stress disorder (PTSD), major depressive disorder, all kinds of anxiety disorders, and some developed substance misuse problems because that was one of the ways they tried to manage the symptoms they had.”

These mental health conditions, combined with the aero-digestive disorders, lymphoma, or lung cancer, which also stem from their work at Ground Zero, have created a complicated set of issues for this aging cohort of responders, many of whom are now in their 50s.

Sandra M. Lowe, MD

“Some members of the public may question the relevance of the WTC Health Center 20 years later,” says Dr. Lowe. “It is very relevant and needed. People are not aware of the ongoing physical or psychological struggles. We see an increased number of patients coming in for help. They have developed worsening physical conditions or now they’re retiring from the New York City Police Department. They may have been suffering PTSD for 20 years, but now they’re no longer afraid of the stigma associated with seeking help. They’ll say, ‘Doc, this is the first time I’ve told anyone about my nightmares.’ We hear the appreciation from the patients and their families.”

As time goes on, Mount Sinai’s clinical team also sees new health issues arising among responders, including the possibility of early cognitive decline. NIOSH is funding studies to determine whether exposure to toxins at Ground Zero is actually associated with this decline and whether there is a need for an early intervention program.

Kathryn Marrone, LCSW, Director of Social Work for the World Trade Center Mental Health Program, joined Mount Sinai in the summer of 2002 for what she was told at the time would be a one-year job monitoring and assessing the needs of responders. Almost two decades later, she is still working with these men and women. Only now, she says, they are aging and require a shift in services.

The responders “recovered bodies, saw people jumping from buildings, and watched the buildings collapse,” she says. “The level of trauma these individuals experienced was quite severe. They were completely confused about how to manage that emotionally.” But over the years, in their dealings with social workers, doctors, and other colleagues in the program, “Mount Sinai has become a lifeline for so many individuals. It is a place where they can turn because no one else quite gets what they’re experiencing.”

Mount Sinai Brings ‘Vaxmobile’ to Community Event in Harlem

Staff from Mount Sinai Morningside, from left: Ruby Guzman, Maytal Rand, and Amy Bush

Mount Sinai Morningside, in collaboration with Mount Sinai South Nassau, participated in Harlem Week’s “A Great Day in Harlem” event on Sunday, August 8, at the Ulysses S. Grant National Memorial.

In partnership with One Hundred Black Men, Mount Sinai premiered a series of videos featuring members of the community and local celebrities encouraging people to protect themselves and their loved ones against COVID-19 by getting vaccinated.

“Thanks to Mount Sinai South Nassau’s vaccination mobile unit—the Vaxmobile—and the incredible staff from Mount Sinai Morningside, we were able to engage residents of Harlem in conversations about the vaccine, and we even provided the vaccine onsite to those ready to roll up their sleeves,” said Amy Bush, Director, Volunteer Services, Mount Sinai Morningside. “In line with the mission of the event, we were honored to have the opportunity to educate attendees, and also give hope to Harlem by spreading immunity in the community.”

Mount Sinai Offers Challenge Coins to Recognize Staff Pandemic Efforts

In July, Mount Sinai Health System’s leadership offered staff the opportunity to receive a Commemorative COVID-19 Challenge Coin to recognize their selfless dedication and commitment during the height of the COVID-19 pandemic in 2020 and 2021.

Challenge Coins, as they have become known, are an important tradition, particularly within the crisis-response community, symbolizing a catastrophic event and recognizing the teamwork and individual sacrifice needed to overcome such events. In the past, they have been given to front-line workers after historical events of importance, such as 9/11 and Hurricane Maria relief efforts in Puerto Rico.

Click here to see three Mount Sinai employees reflecting on challenge coins they received for crisis responses.

In that tradition, this coin is designed to recognize the teamwork and partnership that characterized Mount Sinai’s response to the COVID-19 pandemic. Inscribed on one side of the coin are those exact two words. The opposing side bears a representation of how Mount Sinai’s eight hospitals (marked by eight stars) and hundreds of ambulatory sites—bolstered by clinical, ambulatory, administrative, and operations staff, trainees, and students—united as a system that, together in service, gave and continues to give everything to those who need us most.

Many sites across Mount Sinai hosted events or had managers make rounds to distribute the coins with letters of gratitude. Many other sites are still distributing the coins.

“We offer this small but meaningful token of our deep appreciation. We hope that it will serve as one way to memorialize the remarkable efforts you have made as individuals and as members of a team that met and countered this disastrous pandemic” says Kenneth L. Davis, MD, President and Chief Executive Officer of Mount Sinai Health System.

Making Sense of the Pandemic Now

If you are fully vaccinated, are you protected from COVID-19? Will we need booster shots? What is the best way to keep children safe as they return to school?

These and other pressing questions were discussed in an Aspen Ideas Festival virtual event, in which Kenneth Davis, MD, MD, President and Chief Executive Officer of the Mount Sinai Health System, interviewed Judith A. Aberg, Dean of System Operations for Clinical Sciences, and Chief of the Division of Infectious Diseases, and Harm van Bakel, PhD, Assistant Professor of Genetics and Genomic Sciences and a leader of Mount Sinai’s Pathogen Surveillance Program. The interview, which was released in July, can be viewed here.

Dr. Aberg, who leads Mount Sinai’s COVID-19 clinical trial efforts, shared a favorite analogy about the vaccines’ effectiveness: “An umbrella will keep you dry for the most part, but you can still get wet in a bad storm,” she said. In the same fashion, “the current vaccines are highly effective even for the circulating variants, but we do expect there will be breakthrough infections in some individuals. So I encourage everyone to get vaccinated.”

How Mount Sinai is Transforming Care for Patients with Brain, Spine, and Central Nervous System Disorders

Mount Sinai’s departments of Neurology and Neurosurgery are committed to innovation for the treatment of disorders of the brain, spine, and central nervous system. That commitment has been recognized now that The Mount Sinai Hospital’s Neurology and Neurosurgery departments were ranked for the first time among the top 10 in the nation by U.S. News & World Report.

Joshua B. Bederson, MD

For decades, the departments have expanded clinical and research programs offering ground-breaking treatments for patients with a wide range of conditions, including cancer, brain tumors, and strokes as well as neurological disorders such as Parkinson’s disease, epilepsy, and multiple sclerosis, and psychiatric disorders such as major depression.

“Over the years, this process has involved recruiting the best and brightest neurosurgeons who align with my vision of highly specialized care, centers of excellence, and programs within each subspecialty that are as deep and as broad as an entire neurosurgery department,” says Joshua B. Bederson, MD, Leonard I. Malis, MD / Corinne and Joseph Graber Professor of Neurosurgery and System Chair, Department of Neurosurgery. “It’s also been meaningful to collaborate with the Department of Neurology to support their own recruits and create joint programs that provide comprehensive, well-rounded care to patients with neurological conditions.”

Added Barbara G. Vickrey, MD, MPH, System Chair, Department of Neurology, and Henry P. and Georgette Goldschmidt Professor of Neurology: “Our ranking is an acknowledgement of the Neurology Department’s leadership in clinical care on a national basis. We excel in treating the most challenging neurological patients and providing high-quality care to all of our New York City communities, including those that are under-resourced.”

In this Q&A, Dr. Bederson and Dr. Vickrey discuss how changes they have made over the years have helped patients.

What are some of the most significant changes the Department of Neurosurgery has made?

Over the past several years, our focus has been on building our divisions that deal with different disease states such as brain tumors, vascular problems and stroke, pediatric neurosurgery, movement disorders, and epilepsy. We recruited the nation’s best and brightest leaders in each one of these areas, building programs around their expertise into very strong, and sometimes very large divisions, many of which rival the average neurosurgery department in other parts of this country.

What are some national and global accomplishments?

Some of our national and global accomplishments focus on the creation of the division sub-specializations. In the cerebrovascular space, we recruited one of the world’s great leaders, Dr. J Mocco, to direct our Cerebrovascular Center, and he’s turned it into a very large service line with 10 full-time faculty. We are making groundbreaking changes to clinical treatment, including reducing the “time to needle” and treatment from the onset of stroke down to very low numbers, meaning very fast treatment times. We are achieving results that are the best in the world.

We’ve created centers of excellence around movement disorders, with one of the great deep brain stimulation programs and neurostimulation for intractable epilepsy. We have one of the largest pituitary tumor, skull base surgery, and malignant brain tumor programs in the country, with numerous NIH-funded research studies, and a large number of novel clinical trials in each of these areas. Our Division of Neurocritical Care is a large, world-class division with a unique Neuro Emergencies Management and Transfers (NEMAT) program transferring more than 1,000 patients with critical neurological illness every year.

How does the Department of Neurosurgery advance industry and academia?

Neurosurgery is inherently a technological field, and we rely very heavily on advanced digital and other technologies in the operating room. Through a significant partnership with industry, we have innovated in many creative ways, including in the use of augmented and virtual reality and the use of artificial intelligence that support our advanced digital platforms. We’ve created a new division called Sinai BioDesign, which is an incubator for innovative device creation. Here, surgeons work together with bioengineers to create new solutions for fixing problems that we face in the operating room and turn those solutions into products and companies.

How do these accomplishments result in better outcomes for neurosurgical patients?

All of our activities are aimed at improving patient outcomes. By creating centers of excellence, we can take advantage of our large health system by concentrating normally rare diseases into high volume centers, giving surgeons and other health care professionals the experience they need to become experts. They leverage the high volume to develop clinical protocols and research protocols that allow us to advance care in each disease state. Sinai BioDesign is creating new solutions and devices to help us treat conditions that require new solutions through advanced technologies, improving safety for patients.

Barbara G. Vickrey, MD, MPH

What changes has the Department of Neurology made?

The Neurology Department has grown dramatically in education, research, and clinical care in the last five years. Our department has had an approximately two-and-a-half-fold increase in NIH funding over five years. We have recruited more than 70 new faculty, who have been recruited both internally from our talented Mount Sinai graduates and from major academic institutions around the United States.

What are some specific areas of success?

We strive to improve outcomes in multiple sclerosis, Parkinson’s disease, stroke, epilepsy, headache, neuropathies, brain and spinal cord tumors, dementia, and other neurological disorders in children and adults, and we have subspecialty fellowship training programs in all these areas.  We have well-regarded centers, programs, and divisions that are dedicated to this mission, such as the Corinne Goldsmith Dickinson Center for Multiple Sclerosis, which is known for providing the best available multiple sclerosis care, including access to a wide range of clinical trials and a wellness program.

How does this make a difference for patients?

The Department provides patients with a unique blend of personalized and coordinated care, groundbreaking research, and technology. This integrated approach is instrumental in our pursuit of improving outcomes.

Can you give some examples?

Patients who come to our Comprehensive Stroke Center experience better outcomes on average than those of other New York City hospitals and other comprehensive stroke centers. Our Epilepsy Program provides a spectrum of treatments from the latest medications to vagal nerve stimulation and coordinates with Neurosurgery when surgical intervention is needed, with the goal of living seizure-free. Our patients in any subspecialty can count on physicians who have experience with unusual disorders as well as more common ones. In short, patients can expect to experience the benefits of a large, academic medical center along with personalized care. It’s the best of both worlds.

Should I Tell My Doctor About My Cannabis Use?

Cannabis joint in the hand

Now that New York and many other states around the country have decriminalized medicinal and recreational cannabis, some are interested in partaking. To those people, Yasmin Hurd, PhD, Director of the Addiction Institute of Mount Sinai, advises that marijuana is just like any other drug, even if it’s now legal.

Dr. Hurd is an internationally renowned expert on addiction and related psychiatric disorders who has been at the forefront of research into cannabinoid (CBD), a substance derived from the hemp plant that is now seen in many retail stores. In this Q & A, she explains what you need to know if you are heading to the cannabis dispensary and why disclosing marijuana use to your primary care physician is critical.

What advice do you have for those new to marijuana who are interested in partaking now that recreational use is legal?

You have to really be careful about where you obtain your cannabis. There are bad actors out there, and we have seen that some items which have been marketed as cannabis can actually contain products that are not. Recently, we have seen cannabis that has been laced with fentanyl, which is a highly potent and highly addictive opioid. So, the source from which you obtain your cannabis is critical. For now, the safest way to get marijuana in New York is to get a prescription from a physician and buy it in a state dispensary.

Should I tell my doctor that I am using marijuana? Why?

It is critical to tell your doctor if you are using any cannabis product. Like any drug, cannabis is broken down into various active chemicals that your body can use by liver enzymes. If you are taking any other pharmaceutical drugs, cannabis may interact with the same liver enzymes and either diminish or increase the activity beyond its intended use. So, your doctor absolutely has to know to avoid a potentially dangerous drug interaction.

One of the benefits of legalization is that there should not be any risk in being honest with your doctor about your cannabis use. The more honest that you can be, the better medical care you can receive.

Is it true that marijuana is non-addictive?

Many people don’t realize that you can become addicted to cannabis. In fact, the rate of diagnosis of “cannabis use disorder” is about 30 percent in people who frequently use the drug. That percentage is not much different from highly addictive drugs like cocaine and opioids even though cannabis is not as highly addictive.

The reason that we have such a high prevalence of cannabis use disorder being diagnosed is that a greater number of people use cannabis, so more people can convert into addiction. Often, the higher addiction is due to the higher potency of today’s cannabis.

What specifically is different about today’s marijuana?

Today’s recreational cannabis has a very high concentration of THC (short for delta-9-tetrahydrocannabinol), which is the main psychoactive ingredient in cannabis. It has gone from approximately four percent THC to, in some products, nearly 24 percent. And certain products, even those obtained from dispensaries, could have 70 percent THC. This is much higher than 10 or 20 years ago.

The greater the THC concentration, the greater the potential impact on a user’s mental health, and the greater the potential to become addicted. For a safer, higher-quality product, look for cannabis that has a verified certificate of analysis—this indicates that the product has been thoroughly checked for contaminants, pesticides, and other harmful materials, and it allows you to view its THC levels as well as other ingredients.

Is hemp-based THC safer than cannabis-based THC?

In short, no. THC is the same if purified in a safe manner for human use, whether it is derived from hemp or cannabis. However, the amount of THC that can be produced from hemp is low—the plant contains less than .3 percent THC—, so most THC is obtained from cannabis.

It is important to understand that even though marijuana may be legal for recreational and medicinal purposes in New York, on the federal level it is still a Schedule 1 drug which means that it is considered to have no accepted medical use and a high potential for abuse.

However, CBD—which is derived from hemp—is federally legal. There are some who try to get around cannabis’ federal status by selling a hemp-based THC product under the name ‘delta-8-THC.’ In the cannabis plant, it is delta-9-THC that causes the ‘high’ and, large concentrations of the substance can cause mental health issues. While there is not a lot known about delta-8-THC, we do know that it can cause euphoria, though milder than delta-9-THC.

Many companies are marketing delta-8-THC as the safer—and legal—option, but that is not true. For example, since the amount of THC in the hemp plant is low, some manufacturers try to forego the natural process of deriving the substance and use chemicals to artificially increase the amount of delta-8-THC. Additionally, some bad actor companies are faking their certificate of analysis to say that their product is delta-8-THC, when it turns out that it contains delta-9-THC and harmful materials like lead and heavy metals.

Are there any other drawbacks to frequent cannabis use?

In addition to potentially developing an addiction to cannabis, with use of highly potent cannabis products, we see mental health related problems. For example, issues with attention, memory, and cognition. Those are a side effect of chronic cannabis use, and even occasional use can impair motor issues. We also see the risk for psychosis, especially in certain younger people, when they use cannabis.

And, for any drug that is being consumed by smoking, you also incur the risk of pulmonary issues as smoking which is not good for your lungs.

Has marijuana been proven to alleviate any medical conditions?

There are certain synthetic THC products that have been approved by the U.S. Food and Drug Administration (FDA) for anti-nausea purposes to help increase the appetite of people going through chemotherapy. The FDA has also approved the use of CBD, in particular Epidiolex®, for two rare childhood forms of epilepsy.

Other than that, neither cannabis nor CBD have been approved for anything else. But there are a lot of clinical trials currently being done. So we’ll see how those pan out in a few years.

How does legalizing marijuana benefit the medical community?

Legalizing marijuana is a double-edged sword for the medical community. We want to make sure that people are healthy, and any time you take a drug that you most likely do not need that can have negative effects on mental health, that’s not great. But the legalization of marijuana makes it easier for patients to be honest with their doctors about their cannabis use, which overall gives patients better outcomes because a physician will know exactly what their patient is taking and can, therefore, guide their care in a much better way.

Also, for my fellow researchers, the fact that cannabis is no longer illegal in some states makes it easier for us to investigate what may be the benefits and adverse effects of its use for certain disorders. It also allows us to better guide physicians and their patients about how to use cannabis, if they choose to use cannabis.

Yasmin Hurd, PhD, is the Ward-Coleman Chair of Translational Neuroscience and the Director of the Addiction Institute at Mount Sinai. She is currently the principal investigator on a clinical trial of CBD for treating opioid use disorder, a neuroimaging study of CBD’s effects on the human brain, and a study looking at neurodevelopmental effects of cannabis and its epigenetic regulation.

Pin It on Pinterest